ADIAL PHARMACEUTICALS INC (ADIL) Stock Earnings & Estimates
NASDAQ:ADIL - US00688A2050 - Common Stock
0.3801 USD
+0.01 (+2.15%)
0.3701 USD
-0.01 (-2.63%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 104.26% | N/A 52.08% | N/A 45.89% | N/A 31.92% | |||||||||||
| EBITDA YoY % growth | -800K | -410K 48.75% | -1M -143.90% | -6.99M -599.00% | -8.24M -17.88% | -10.93M -32.65% | -17.73M -62.21% | -13.31M 24.93% | -6.887M 48.25% | -8.284M -20.28% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -800K | -410K 48.75% | -1M -143.90% | -6.99M -599.00% | -8.24M -17.88% | -10.93M -32.65% | -17.74M -62.31% | -13.32M 24.92% | -6.888M 48.29% | -8.285M -20.27% | N/A 0.41% | N/A -100.94% | N/A -27.85% | N/A 148.12% | N/A 290.00% | N/A 41.03% | N/A 112.73% | N/A 32.48% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -0.86 | N/A -2,746.51% | -13.00 46.90% | -4.32 66.77% | -1.91 55.79% | N/A 53.27% | N/A -14.29% | N/A 45.00% | N/A 100.00% | N/A | N/A 100.00% | N/A 1,067.50% | N/A 23.13% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.19 46.09% | -0.19 46.09% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.179M 1.45% | -2.21M -13.88% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.18 69.49% | -0.26 | 0.08 | 29.41% |
| Q1 2025 Q2Q % growth | -0.34 45.16% | -0.50 | 0.16 | 32.66% |
| Q4 2024 Q2Q % growth | -0.35 74.07% | -0.39 | 0.04 | 9.70% |
| Q3 2024 Q2Q % growth | -0.35 70.34% | -0.39 | 0.04 | 9.70% |
| Q2 2024 Q2Q % growth | -0.59 -161.46% | -0.55 | -0.04 | -8.12% |
| Q1 2024 Q2Q % growth | -0.62 77.45% | -0.34 | -0.28 | -84.19% |
| Q4 2023 Q2Q % growth | -1.35 50.91% | -0.78 | -0.57 | -74.15% |
| Q3 2023 Q2Q % growth | -1.18 60.67% | -1.16 | -0.02 | -1.93% |
| Q2 2023 Q2Q % growth | 0.96 124.00% | -1.53 | 2.49 | 162.75% |
| Q1 2023 Q2Q % growth | -2.75 15.38% | -3.57 | 0.82 | 22.97% |
| Q4 2022 Q2Q % growth | -2.75 60.85% | -3.83 | 1.08 | 28.10% |
| Q3 2022 Q2Q % growth | -3.00 -1,263.64% | -4.59 | 1.59 | 34.64% |
| Q2 2022 Q2Q % growth | -4.00 -1,500.00% | -3.70 | -0.30 | -8.18% |
| Q1 2022 Q2Q % growth | -3.25 -2,024.18% | -4.34 | 1.09 | 25.03% |
| Q4 2021 Q2Q % growth | -7.03 -2,827.08% | -5.27 | -1.75 | -33.30% |
| Q3 2021 Q2Q % growth | -0.22 8.33% | -0.22 | 0.00 | 1.96% |
| Q2 2021 Q2Q % growth | -0.25 -56.25% | -0.21 | -0.04 | -19.56% |
| Q1 2021 Q2Q % growth | 30.45% | -0.15 | % | |
| Q4 2020 Q2Q % growth | -0.24 | -0.26 | 0.02 | 5.88% |
| Q3 2020 Q2Q % growth | -0.24 -41.18% | -0.18 | -0.06 | -30.72% |
| Q2 2020 Q2Q % growth | -0.16 23.81% | -0.18 | 0.02 | 12.85% |
| Q1 2020 Q2Q % growth | -0.22 18.52% | % | ||
| Q2 2019 Q2Q % growth | -0.21 | -0.18 | -0.03 | -14.38% |
| Q1 2019 Q2Q % growth | -0.27 | -0.17 | -0.10 | -55.71% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 40.32% | 1.13% | 49.9% |
| Revenue | N/A | N/A | N/A | N/A |